Publication | Open Access

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Surgical OncologyOncologyPrado TrialMelanomaClinical TrialsNeoadjuvant IpilimumabImmune Checkpoint InhibitorDermatologyCancer TreatmentImmunotherapyMedicineResponse-directed SurgerySkin Cancer